JP2022500437A5 - - Google Patents

Info

Publication number
JP2022500437A5
JP2022500437A5 JP2021514112A JP2021514112A JP2022500437A5 JP 2022500437 A5 JP2022500437 A5 JP 2022500437A5 JP 2021514112 A JP2021514112 A JP 2021514112A JP 2021514112 A JP2021514112 A JP 2021514112A JP 2022500437 A5 JP2022500437 A5 JP 2022500437A5
Authority
JP
Japan
Prior art keywords
peptide
hyp
lys
virus
containing compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514112A
Other languages
English (en)
Japanese (ja)
Other versions
JP7759693B2 (ja
JP2022500437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/105832 external-priority patent/WO2020052677A1/en
Publication of JP2022500437A publication Critical patent/JP2022500437A/ja
Publication of JP2022500437A5 publication Critical patent/JP2022500437A5/ja
Application granted granted Critical
Publication of JP7759693B2 publication Critical patent/JP7759693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514112A 2018-09-14 2019-09-14 モンテルカストおよびペプチドの新規接合体 Active JP7759693B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018105703 2018-09-14
CNPCT/CN2018/105703 2018-09-14
CN2018119072 2018-12-04
CNPCT/CN2018/119072 2018-12-04
PCT/CN2019/105832 WO2020052677A1 (en) 2018-09-14 2019-09-14 New conjugates of montelukast and peptides

Publications (3)

Publication Number Publication Date
JP2022500437A JP2022500437A (ja) 2022-01-04
JP2022500437A5 true JP2022500437A5 (cg-RX-API-DMAC7.html) 2022-09-21
JP7759693B2 JP7759693B2 (ja) 2025-10-24

Family

ID=69777394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514112A Active JP7759693B2 (ja) 2018-09-14 2019-09-14 モンテルカストおよびペプチドの新規接合体

Country Status (27)

Country Link
US (2) US11680082B2 (cg-RX-API-DMAC7.html)
EP (2) EP3678705B1 (cg-RX-API-DMAC7.html)
JP (1) JP7759693B2 (cg-RX-API-DMAC7.html)
KR (1) KR102946621B1 (cg-RX-API-DMAC7.html)
CN (2) CN111601618A (cg-RX-API-DMAC7.html)
AU (1) AU2019338582B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004823A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112420A1 (cg-RX-API-DMAC7.html)
DK (1) DK3678705T5 (cg-RX-API-DMAC7.html)
ES (1) ES2956509T3 (cg-RX-API-DMAC7.html)
FI (1) FI3678705T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230946T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062848T2 (cg-RX-API-DMAC7.html)
IL (1) IL281426A (cg-RX-API-DMAC7.html)
LT (1) LT3678705T (cg-RX-API-DMAC7.html)
MX (1) MX2021002657A (cg-RX-API-DMAC7.html)
MY (1) MY205435A (cg-RX-API-DMAC7.html)
PL (1) PL3678705T3 (cg-RX-API-DMAC7.html)
PT (1) PT3678705T (cg-RX-API-DMAC7.html)
RS (1) RS64436B1 (cg-RX-API-DMAC7.html)
SA (1) SA521421448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102119RA (cg-RX-API-DMAC7.html)
SI (1) SI3678705T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300210T1 (cg-RX-API-DMAC7.html)
TW (1) TWI875712B (cg-RX-API-DMAC7.html)
WO (1) WO2020052677A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101398B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
EP4028409A4 (en) * 2019-09-14 2023-10-11 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. NEW PEPTIDES
US20240218016A1 (en) * 2019-12-02 2024-07-04 Shenzhen Institutes Of Advanced Technology Peptides and their use in the treatment of inflammation
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2021207606A1 (en) * 2020-04-10 2021-10-14 University Of Georgia Research Foundation, Inc. Methods for treatment of coronavirus infections
KR102596264B1 (ko) * 2020-11-30 2023-11-01 주식회사 바이오빛 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
WO2022193185A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates
WO2023225107A1 (en) * 2022-05-17 2023-11-23 Emory University Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions
JP2026506026A (ja) * 2023-02-13 2026-02-20 エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド 新規多機能オリゴペプチド
AU2024312518A1 (en) * 2023-06-22 2026-01-22 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
CN122028898A (zh) * 2023-10-23 2026-05-12 艾缇亚(上海)制药有限公司 新型短链肽及其衍生物
WO2025110754A1 (ko) * 2023-11-22 2025-05-30 한도숙 상처 치료 또는 피부 주름형성 억제용 조성물
WO2025195444A1 (en) 2024-03-20 2025-09-25 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New use of peptides derived from vasoactive intestinal peptide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2003020200A2 (en) 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2004005309A2 (en) 2002-07-08 2004-01-15 Pliva - Istrazivacki Institut D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
US7582297B2 (en) * 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
JP2007510621A (ja) 2003-07-29 2007-04-26 シグニチャー アールアンドディー ホールディングス,エルエルシー. アミノ酸プロドラッグ
DE602005018672D1 (de) * 2004-10-27 2010-02-11 Glaxosmithkline Zagreb Konjugate mit entzündungshemmender aktivität
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CA2773737C (en) * 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
CN102068432A (zh) 2011-01-11 2011-05-25 李仲昆 一种由他定类和白三烯拮抗剂组成的外用复方组合物
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
HK1207562A1 (en) 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
EP2968309A4 (en) * 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
US20160060328A1 (en) * 2013-10-25 2016-03-03 Lpath, Inc. Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
BR112018000953A2 (pt) 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
CN110945016A (zh) 2017-05-24 2020-03-31 特拉斯福特普拉斯公司 用于治疗炎性疾病的肽化合物、缀合化合物及其用途
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
CN110139662B (zh) * 2017-07-05 2022-03-18 江阴贝瑞森制药有限公司 肽的抗炎用途

Similar Documents

Publication Publication Date Title
FI3678705T3 (fi) Montelukastin ja peptidien konjugaatteja
CN105143170B (zh) 用于治疗肺纤维化、肝纤维化、皮肤纤维化和心脏纤维化的经取代的芳族化合物
US12612430B2 (en) Peptides
JP2021525242A5 (cg-RX-API-DMAC7.html)
JP2023503380A5 (cg-RX-API-DMAC7.html)
CN113272298B (zh) 用于治疗呼吸系统疾病的化合物和组合物
JP2026067913A (ja) 新規なペプチドと多糖類とのコンジュゲート
WO2023169557A1 (zh) 一种次黄碱衍化合物在制备治疗肺纤维化药物中的应用
KR20250143851A (ko) 신규한 다기능성 올리고펩타이드
RU2021105972A (ru) Новые конъюгаты монтелукаста и пептидов
CN110753688A (zh) 用于治疗呼吸系统疾病的化合物
JP2024506291A5 (cg-RX-API-DMAC7.html)
MD3678705T2 (ro) Conjugați de montelukast și peptide
EA038170B1 (ru) Составы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
JP2003502441A (ja) サーファクタントタンパク質cエステル